title: Pharmacokinetics of testosterone in hypogonadal men after transdermal delivery: influence of dose.
abstract: To assess the pharmacokinetics of testosterone after application of one, two, or three testosterone transdermal delivery systems to hypogonadal patients, 12 hypogonadal men (mean age 46.6 +/- 10.5 years) were enrolled in an open-label, randomized, crossover study. Each application period comprised 4 days: a 2-day washout period with no exogenous testosterone therapy followed by 2 days of therapy with one, two, or three transdermal systems applied daily to the patient's back. On day 4 of each period, serial blood samples were collected for determination of total and non-sex hormone binding globulin (non-SHBG) bound serum testosterone concentrations. Serum concentrations of testosterone were determined using validated radioimmunoassay methods. Residual testosterone analysis of used transdermal systems was used to estimate testosterone delivery through the skin. In general, serum concentrations of testosterone rose in accordance with an increase in dose. Using a strict bioequivalence approach to dose proportionality, the increases in area under the concentration-time curve (AUC) and morning concentrations were proportional to the increase in dose from two to three transdermal systems, but somewhat less than proportional with an increase from one to two transdermal systems. Results from the non-SHBG bound serum testosterone concentrations closely paralleled those of total serum testosterone. Use of three transdermal systems yielded serum concentrations of testosterone that tended to be above the upper limit of the normal range. The AUC and cumulative release of testosterone were linearly related to the number of applied systems. If necessary, the standard recommended dose of two testosterone transdermal delivery systems can be modified to accommodate interindividual differences in testosterone requirements of hypogonadal men.
authors.affiliation: Department of Drug Metabolism and Pharmacokinetics, SmithKline Beecham Pharmaceuticals, King of Prussia, Pennsylvania, USA.
authors.forename: D R
authors.initials: DR
authors.lastname: Brocks
authors.forename: A W
authors.initials: AW
authors.lastname: Meikle
authors.forename: S C
authors.initials: SC
authors.lastname: Boike
authors.forename: N A
authors.initials: NA
authors.lastname: Mazer
authors.forename: N
authors.initials: N
authors.lastname: Zariffa
authors.forename: P R
authors.initials: PR
authors.lastname: Audet
authors.forename: D K
authors.initials: DK
authors.lastname: Jorkasky
mesh_terms: D000279:Administration, Cutaneous; D000328:Adult; D019540:Area Under Curve; D004305:Dose-Response Relationship, Drug; D006801:Humans; D007006:Hypogonadism / Q000188:drug therapy / Q000378:metabolism*; D008297:Male; D008657:Metabolic Clearance Rate; D008875:Middle Aged; D013739:Testosterone / Q000008:administration & dosage / Q000493:pharmacokinetics*
chemical_list: D013739:Testosterone